Company: KAVL
Filing Date: 2025-08-18
Form Type: 424B5
Source: 0001731122-25-001141
Chunk: 12

Company: Kaival Brands Innovations Group, Inc.
Filing Date: 2025-08-18
Form: 424B5
Chunk 12
---
 of proceeds                                                         | We currently intend to use the net proceeds from this offering for working capital and general corporate purposes. See “Use of Proceeds.”                                                                                                                                                                                                                                                                                                                                                   |
| Risk factors                                                            | You should read the “Risk Factors” section on page S-7 of this prospectus supplement, page 12 of the accompanying base prospectus and/or similar headings in the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock.                                                                                                                     |
| Nasdaq Trading Symbol                                                   | “KAVL”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

Unless we indicate otherwise, all information in this prospectus is based on 11,542,302
shares outstanding as of August 15, 2025. The number of shares outstanding as used throughout this prospectus supplement, unless otherwise
indicated, excludes, as of that date:

| ● | 357,120 shares of our common stock issuable upon conversion of 900,000 outstanding shares of Series B Preferred Stock;                            |
| ● | 119,953 shares of our common stock issuable upon exercise of stock options outstanding, at a weighted average exercise price of $27.95 per share  |
| ● | 5,754,686 shares of our common stock issuable upon the exercise of warrants outstanding, at a weighted average exercise price of $3.45 per share. |
| ● | 99,732,179 shares of our common stock reserved for future issuance under our Amended and Restated 2020 Stock and Incentive Compensation Plan      |

<div align='center'>6

RISK FACTORS</div>

Investing in our shares of common stock involves a high degree of risk, and you should be able to bear the complete loss of your investment. You should consider carefully the risks described below and those described under the section captioned “Risk Factors” contained in our most recent Annual Report on Form 10-K for the year ended October 31, 2024, any subsequent Quarterly Reports on Form 10-Q, and all other information contained or incorporated by reference into this prospectus supplement and the accompanying base prospectus before deciding whether to purchase any of the common stock being offered under this prospectus supplement. If any of the risks actually occur, our business, financial condition or results of operations could be adversely affected. In such case, the trading price of our common stock could decline and you could lose all or part of your investment. Our actual